Alzamend Neuro Inc Total Liabilities
Alzamend Neuro Inc total liabilities. Based on the latest financial reports, Alzamend Neuro Inc (ALZN) has total liabilities worth $2.74 Million USD as of July 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Alzamend Neuro Inc (ALZN) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Alzamend Neuro Inc (2016–2026)
Total liabilities of Alzamend Neuro Inc from 2016 to 2026. This chart illustrates how Alzamend Neuro Inc's total liabilities have evolved over time, based on quarterly financial data.
Alzamend Neuro Inc Competitors by Total Liabilities
The table below lists competitors of Alzamend Neuro Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Skyline Investment S.A.
WAR:SKL
|
Poland | zł14.64 Million |
|
MSCM Holdings Bhd
KLSE:0041
|
Malaysia | RM78.65 Million |
|
Fidelity Emerging Markets Ord
LSE:FEML
|
UK | GBX16.96 Million |
|
Schroders Investment Trusts - Schroder Asian Total Return Investment Company plc
LSE:ATR
|
UK | GBX3.77 Million |
|
FUXING CHINA GRP SD 5
F:3FU1
|
Germany | €231.76 Million |
|
JX Luxventure Limited
NASDAQ:JXG
|
USA | $7.55 Million |
|
Bt Brands Inc
NASDAQ:BTBD
|
USA | $4.33 Million |
Liability Composition Analysis (2016–2026)
This chart breaks down Alzamend Neuro Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ALZN asset base.
Liquidity & Leverage Metrics
Alzamend Neuro Inc Total Liabilities Ratios Explained
Alzamend Neuro Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alzamend Neuro Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alzamend Neuro Inc (2016–2026)
The table below shows the annual total liabilities of Alzamend Neuro Inc from 2016 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-04-30 | $1.35 Million | +112.07% |
| 2025-04-30 | $634.76K | -80.32% |
| 2024-04-30 | $3.23 Million | +12.39% |
| 2023-04-30 | $2.87 Million | +146.38% |
| 2022-04-30 | $1.16 Million | +29.49% |
| 2021-04-30 | $899.64K | -9.34% |
| 2020-04-30 | $992.31K | -16.19% |
| 2019-04-30 | $1.18 Million | +1124.10% |
| 2018-04-30 | $96.72K | -86.51% |
| 2017-04-30 | $717.22K | +2234.71% |
| 2016-04-30 | $30.72K | -- |
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, … Read more